World

Israeli aid suspensions will make situation in Gaza even worse: UN rights chief

Jan 01, 2026

Tel Aviv [Israel], January 1: UN rights chief Volker Turk calld Israel's threat to suspend aid groups from operating in Gaza from January 1 "outrageous".
"Israel's suspension of numerous aid agencies from Gaza is outrageous," Turk said in a statement. "Such arbitrary suspensions make an already intolerable situation even worse for the people of Gaza," he warned.
Israel announced that unless 37 aid organisations comply with new guidelines, which require detailed information on Palestinian staff, they will be banned from operating in Gaza. "This is the latest in a pattern of unlawful restrictions on humanitarian access," Turk said, pointing to Israel's ban on the UN agency for Palestinian refugees, UNRWA, and "attacks on Israeli and Palestinian NGOs amid broader access issues faced by the UN and other humanitarians".
"I urge all States, in particular those with influence, to take urgent steps and insist that Israel immediately allows aid to get into Gaza unhindered," he said.
Philippe Lazzarini, the commissioner-general of UNRWA, said Israel's suspension of 37 aid organisations in Gaza shows "a troubling pattern of disregard for international humanitarian law". "This is a dangerous precedent," Lazzarini wrote on social media platform X. "Failing to push back against attempts to control the work of aid organisations will further undermine the basic humanitarian principles of neutrality, independence, impartiality and humanity underpinning aid work across the world." (Agencies)
Source: Qatar Tribune

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026